BR112023025433A2 - Anticorpos anti-ccr8 e seus usos - Google Patents
Anticorpos anti-ccr8 e seus usosInfo
- Publication number
- BR112023025433A2 BR112023025433A2 BR112023025433A BR112023025433A BR112023025433A2 BR 112023025433 A2 BR112023025433 A2 BR 112023025433A2 BR 112023025433 A BR112023025433 A BR 112023025433A BR 112023025433 A BR112023025433 A BR 112023025433A BR 112023025433 A2 BR112023025433 A2 BR 112023025433A2
- Authority
- BR
- Brazil
- Prior art keywords
- ccr8 antibodies
- ccr8
- antibodies
- antigen
- binding fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163197271P | 2021-06-04 | 2021-06-04 | |
| US202163236551P | 2021-08-24 | 2021-08-24 | |
| PCT/US2022/032011 WO2022256563A1 (en) | 2021-06-04 | 2022-06-02 | Anti-ccr8 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023025433A2 true BR112023025433A2 (pt) | 2024-02-27 |
Family
ID=82358418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023025433A BR112023025433A2 (pt) | 2021-06-04 | 2022-06-02 | Anticorpos anti-ccr8 e seus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12258411B2 (https=) |
| EP (1) | EP4347655A1 (https=) |
| JP (1) | JP2024522360A (https=) |
| KR (1) | KR20240017912A (https=) |
| AU (1) | AU2022285741A1 (https=) |
| BR (1) | BR112023025433A2 (https=) |
| CA (1) | CA3222764A1 (https=) |
| CL (2) | CL2023003607A1 (https=) |
| CO (1) | CO2023018064A2 (https=) |
| CR (1) | CR20230581A (https=) |
| IL (1) | IL308808A (https=) |
| JO (1) | JOP20230312A1 (https=) |
| MX (1) | MX2023014458A (https=) |
| PE (1) | PE20240363A1 (https=) |
| TW (1) | TW202313684A (https=) |
| UY (1) | UY39798A (https=) |
| WO (1) | WO2022256563A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024522360A (ja) * | 2021-06-04 | 2024-06-18 | アムジエン・インコーポレーテツド | 抗ｃｃｒ８抗体及びその使用 |
| JP2025537137A (ja) * | 2022-11-04 | 2025-11-14 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法 |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| JPWO2024248037A1 (https=) | 2023-05-30 | 2024-12-05 | ||
| WO2024255753A1 (zh) * | 2023-06-12 | 2024-12-19 | 南京蓬勃生物科技有限公司 | 结合人ccr8的抗体及其用途 |
| TW202529804A (zh) | 2023-10-06 | 2025-08-01 | 美商安進公司 | 用於癌症治療的組合療法 |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2025186043A1 (en) | 2024-03-06 | 2025-09-12 | Bayer Aktiengesellschaft | Pharmaceutical formulation for anti-ccr8 antibodies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025259871A1 (en) | 2024-06-14 | 2025-12-18 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| WO2007044756A2 (en) | 2005-10-11 | 2007-04-19 | Icos Corporation | Monoclonal antibodies recognizing human ccr8 |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| ES2593484T3 (es) | 2007-03-29 | 2016-12-09 | Genmab A/S | Anticuerpos biespecíficos y métodos de producción de los mismos |
| HRP20241208T1 (hr) | 2010-04-20 | 2024-11-22 | Genmab A/S | Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju |
| EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| US10087259B1 (en) | 2014-04-28 | 2018-10-02 | Memorial Sloan Kettering Cancer Center | Depleting tumor-specific tregs |
| MA41044A (fr) * | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| JP2018515474A (ja) * | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| ES2863412T3 (es) | 2017-03-29 | 2021-10-11 | Shionogi & Co | Composición farmacéutica para el tratamiento del cáncer |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| CN110835371A (zh) | 2018-08-19 | 2020-02-25 | 普米斯生物技术(苏州)有限公司 | 抗ccr8单克隆抗体及其应用 |
| WO2020138489A1 (ja) * | 2018-12-27 | 2020-07-02 | 塩野義製薬株式会社 | 新規抗ｃｃｒ８抗体 |
| CA3160204A1 (en) | 2020-01-06 | 2021-07-15 | Vaccinex, Inc. | Anti-ccr8 antibodies and uses thereof |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| AU2021244200A1 (en) | 2020-03-23 | 2022-11-24 | Bristol-Myers Squibb Company | Anti-CCR8 antibodies for treating cancer |
| TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
| WO2022004760A1 (ja) | 2020-06-30 | 2022-01-06 | 塩野義製薬株式会社 | 抗ｃｃｒ８抗体と化学療法剤の併用 |
| WO2022003156A1 (en) | 2020-07-02 | 2022-01-06 | Oncurious Nv | Ccr8 non-blocking binders |
| US20230322955A1 (en) | 2020-08-20 | 2023-10-12 | Amgen Inc. | Antigen binding proteins with non-canonical disulfide in fab region |
| EP4186926A4 (en) | 2020-08-28 | 2024-06-05 | Harbour Biomed US, Inc. | ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION |
| CA3198456A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| EP4010378B1 (en) | 2020-10-16 | 2026-05-06 | LaNova Medicines Limited | Anti-ccr8 monoclonal antibodies and uses thereof |
| EP4267621A1 (en) | 2020-12-24 | 2023-11-01 | Vib Vzw | Murine cross-reactive human ccr8 binders |
| CA3206124A1 (en) | 2020-12-24 | 2022-06-30 | Vib Vzw | Non-blocking human ccr8 binders |
| WO2022136647A1 (en) | 2020-12-24 | 2022-06-30 | Oncurious Nv | Human ccr8 binders |
| JP2024522360A (ja) * | 2021-06-04 | 2024-06-18 | アムジエン・インコーポレーテツド | 抗ｃｃｒ８抗体及びその使用 |
| JP2024520666A (ja) * | 2021-06-04 | 2024-05-24 | アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔ細胞エンゲージャ分子及びその使用 |
-
2022
- 2022-06-02 JP JP2023574361A patent/JP2024522360A/ja active Pending
- 2022-06-02 UY UY0001039798A patent/UY39798A/es unknown
- 2022-06-02 CA CA3222764A patent/CA3222764A1/en active Pending
- 2022-06-02 PE PE2023003211A patent/PE20240363A1/es unknown
- 2022-06-02 KR KR1020247000218A patent/KR20240017912A/ko active Pending
- 2022-06-02 EP EP22736093.0A patent/EP4347655A1/en active Pending
- 2022-06-02 BR BR112023025433A patent/BR112023025433A2/pt unknown
- 2022-06-02 MX MX2023014458A patent/MX2023014458A/es unknown
- 2022-06-02 WO PCT/US2022/032011 patent/WO2022256563A1/en not_active Ceased
- 2022-06-02 US US17/831,398 patent/US12258411B2/en active Active
- 2022-06-02 CR CR20230581A patent/CR20230581A/es unknown
- 2022-06-02 AU AU2022285741A patent/AU2022285741A1/en active Pending
- 2022-06-02 IL IL308808A patent/IL308808A/en unknown
- 2022-06-02 TW TW111120681A patent/TW202313684A/zh unknown
-
2023
- 2023-11-29 JO JOJO/P/2023/0312A patent/JOP20230312A1/ar unknown
- 2023-12-04 CL CL2023003607A patent/CL2023003607A1/es unknown
- 2023-12-20 CO CONC2023/0018064A patent/CO2023018064A2/es unknown
-
2024
- 2024-11-20 CL CL2024003552A patent/CL2024003552A1/es unknown
-
2025
- 2025-01-28 US US19/039,566 patent/US20250171549A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003607A1 (es) | 2024-06-07 |
| US20250171549A1 (en) | 2025-05-29 |
| EP4347655A1 (en) | 2024-04-10 |
| WO2022256563A1 (en) | 2022-12-08 |
| MX2023014458A (es) | 2023-12-15 |
| JP2024522360A (ja) | 2024-06-18 |
| AU2022285741A1 (en) | 2023-12-14 |
| KR20240017912A (ko) | 2024-02-08 |
| US12258411B2 (en) | 2025-03-25 |
| CO2023018064A2 (es) | 2024-01-15 |
| CA3222764A1 (en) | 2022-12-08 |
| TW202313684A (zh) | 2023-04-01 |
| US20220403037A1 (en) | 2022-12-22 |
| UY39798A (es) | 2022-12-30 |
| JOP20230312A1 (ar) | 2023-11-29 |
| CR20230581A (es) | 2024-02-13 |
| PE20240363A1 (es) | 2024-03-04 |
| CL2024003552A1 (es) | 2025-08-01 |
| IL308808A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023025433A2 (pt) | Anticorpos anti-ccr8 e seus usos | |
| MX2021015024A (es) | Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos. | |
| BR112021012027A2 (pt) | Molécula bifuncional direcionada contra pd-1 humano | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| DOP2020000245A (es) | Anticuerpos il-11 | |
| CL2020003391A1 (es) | Proteína de unión al antígeno anti-steap1 | |
| ECSP20076683A (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| DOP2020000236A (es) | Anticuerpos il-1 1ra | |
| CO2021000419A2 (es) | Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| IL281778A (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| BR112021004316A2 (pt) | Anticorpos de agonistas anti-trem-2 | |
| MX2021012692A (es) | Anticuerpos anti-mertk y sus metodos de uso. | |
| MX2020010881A (es) | Construcciones de anticuerpos anti-ror. | |
| BR112018014760A2 (pt) | anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos | |
| BR112016022841A8 (pt) | Anticorpo igm, iga, igg / igm ou igg / iga, ou um fragmento de ligação ao antígeno do mesmo, composição que o compreende e uso do mesmo | |
| UY37591A (es) | Conjugados de fármaco anticuerpo | |
| BR112018075651A2 (pt) | anticorpos anti-cd98 e conjugados anticorpo fármaco | |
| BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
| MX2020009465A (es) | Anticuerpos anti-klk5 y metodos de uso. | |
| BR112022006620A2 (pt) | Anticorpos contra o receptor de poliovírus (pvr) e seus usos | |
| MX2021015156A (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos. | |
| CL2021001607A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| IL286690A (en) | Anti-egfrviii antibodies and antigen-binding fragments thereof | |
| MX2022002672A (es) | Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo. |